194 related articles for article (PubMed ID: 8632731)
1. Glimepiride for NIDDM.
Med Lett Drugs Ther; 1996 May; 38(975):47-8. PubMed ID: 8632731
[No Abstract] [Full Text] [Related]
2. Rosiglitazone/glimepiride (Avandaryl) for diabetes.
Med Lett Drugs Ther; 2006 Mar; 48(1230):22-4. PubMed ID: 16538189
[No Abstract] [Full Text] [Related]
3. Pioglitazone/glimepiride (Duetact) for diabetes.
Med Lett Drugs Ther; 2007 Jan; 49(1253):9-11. PubMed ID: 17261966
[No Abstract] [Full Text] [Related]
4. Sulphonylureas in the treatment of non-insulin-dependent diabetes.
Ferner RE; Alberti KG
Q J Med; 1989 Nov; 73(271):987-95. PubMed ID: 2695959
[No Abstract] [Full Text] [Related]
5. [Hypoglycemic sulfamides: new pharmacologic data and practical implications].
Blickle JF; Brogard JM
Diabetes Metab; 1998 Jun; 24(3):276-80. PubMed ID: 9690064
[No Abstract] [Full Text] [Related]
6. Oral hypoglycemic agents in type II diabetes mellitus.
Lubbos H; Miller JL; Rose LI
Am Fam Physician; 1995 Nov; 52(7):2075-8. PubMed ID: 7484707
[TBL] [Abstract][Full Text] [Related]
7. Pioglitazone + glimepiride: a combination product to avoid.
Prescrire Int; 2007 Aug; 16(90):145. PubMed ID: 17724836
[No Abstract] [Full Text] [Related]
8. Rosiglitazone + glimepiride: new drug. Another combination product to avoid.
Prescrire Int; 2007 Aug; 16(90):144. PubMed ID: 17726795
[No Abstract] [Full Text] [Related]
9. Use oral hypoglycemics with caution..
Jackson JE; Bressler R
Geriatrics; 1988 Aug; 43(8):77-83. PubMed ID: 3136057
[No Abstract] [Full Text] [Related]
10. [Glimepiride--an oral antidiabetic agent].
Becić F; Kapić E; Becić E
Med Arh; 2003; 57(2):125-7. PubMed ID: 12822388
[TBL] [Abstract][Full Text] [Related]
11. Sulfonylureas.
Zimmerman BR
Endocrinol Metab Clin North Am; 1997 Sep; 26(3):511-22. PubMed ID: 9314012
[TBL] [Abstract][Full Text] [Related]
12. Update on oral hypoglycemics (continuing education credit).
White JR
J Pract Nurs; 1994 Mar; 44(1):24-31; quiz 31-3. PubMed ID: 8158562
[No Abstract] [Full Text] [Related]
13. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
Standl E; Schnell O
Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
[No Abstract] [Full Text] [Related]
14. Possible risk of sulphonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease.
Fasching P
Diabetologia; 1998 Jun; 41(6):743-4. PubMed ID: 9662063
[No Abstract] [Full Text] [Related]
15. [Glimepiride in daily practice].
Jasik M
Przegl Lek; 2003; 60(6):409-12. PubMed ID: 14974179
[TBL] [Abstract][Full Text] [Related]
16. Clinical profile of the novel sulphonylurea glimepiride.
Rosskamp R; Wernicke-Panten K; Draeger E
Diabetes Res Clin Pract; 1996 Jul; 31 Suppl():S33-42. PubMed ID: 8864639
[TBL] [Abstract][Full Text] [Related]
17. Treating type 2 diabetes: targeting the many causative factors.
Sutherland JE; Hoehns JD
J Fam Pract; 2004 May; 53(5):376-88. PubMed ID: 15125823
[No Abstract] [Full Text] [Related]
18. Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients.
Holstein A; Hammer C; Hahn M; Kulamadayil NS; Kovacs P
Expert Opin Drug Saf; 2010 Sep; 9(5):675-81. PubMed ID: 20553106
[TBL] [Abstract][Full Text] [Related]
19. Glimepiride-induced vasculitis: a case report.
Ben Salem C; Hmouda H; Bouraoui K
Br J Clin Pharmacol; 2007 Jul; 64(1):113-4. PubMed ID: 17324240
[No Abstract] [Full Text] [Related]
20. [Hardly any hypoglycemias, constant weight--and still cost effective].
MMW Fortschr Med; 2005 Nov; 147(47):72-3. PubMed ID: 16370200
[No Abstract] [Full Text] [Related]
[Next] [New Search]
